CIK 0001806310
- Non-accelerated filer
- Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 843199512
- Phone
- +1 214-612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 1,500,000 shares at $2.00 ($3,000,000)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 3,325 shares at $3.47 ($11,538)
- 4 Open-market sale Chief Financial Officer sold 28,675 shares at an average $3.70 ($105,999)
- 4 Open-market sale CMO and Head of R&D sold 12,861 shares at an average $3.70 ($47,650)
- 4 Open-market sale CMO and Head of R&D sold 50,139 shares at an average $3.65 ($183,081)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 201,602 shares at an average $7.80 ($1,571,810)
Page 4 of 6 · 120 filings